Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Nephrol. Sep 25, 2025; 14(3): 102667
Published online Sep 25, 2025. doi: 10.5527/wjn.v14.i3.102667
Published online Sep 25, 2025. doi: 10.5527/wjn.v14.i3.102667
Antimicrobial dosing considerations in critically ill patients with acute kidney injury: A review
Caroline Tee, Melissa Ngai, Department of Pharmacy, National University Hospital, Singapore 119074, Singapore
Kay Choong See, Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore 119074, Singapore
Author contributions: Tee C wrote the manuscript; Ngai M participated in drafting sections and reviewing written content; See KC provided supervision and revised the manuscript.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Caroline Tee, PharmD, Department of Pharmacy, National University Hospital, 5 Lower Kent Ridge Road, Singapore 119074, Singapore. caroline_tee@nuhs.edu.sg
Received: October 25, 2024
Revised: March 9, 2025
Accepted: April 2, 2025
Published online: September 25, 2025
Processing time: 327 Days and 16.4 Hours
Revised: March 9, 2025
Accepted: April 2, 2025
Published online: September 25, 2025
Processing time: 327 Days and 16.4 Hours
Core Tip
Core Tip: Currently, there are few published reviews focusing on dosing considerations for critically ill patients with acute kidney injury across key antimicrobial categories, including antibiotics, antivirals, and antifungals. Recognizing how physiological changes affect drug-related pharmacokinetics and pharmacodynamics in this context can help guide dosing strategies to enhance clinical outcomes for these patients.